
Eli Lilly’s Bold Moves: Biotech Acquisition and Strategic Price Cuts Boost Stock
Eli Lilly’s stock surged by 2.6% following strategic moves in the pharmaceutical sector. The company acquired Organovo’s FXR program, targeting ulcerative colitis and metabolic